 |
|
|
|
|
Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the Infectious disease and Respiratory (ID&R) pharmaceutical
analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Market definition for this report
- Objective of the analysis
- Strategic scoping and focus
- Data definitions, limitations and assumptions
- Standard units
- Derivation of Pricing Trends
- Datamonitor insight into the portable inhaler devices market
- Contributing experts
- Related reports
- Upcoming related reports
- CHAPTER 2 PORTABLE INHALER DEVICES OVERVIEW
- Metered dose inhalers
- Pressurized metered dose inhalers
- Breath-activated metered dose inhalers
- Dry powder inhalers
- Single-unit dose DPIs
- Multi-dose reservoir DPIs
- Multi-unit dose DPIs
- Advantages
- DPIs do not require actuation-inhalation co-ordination like pMDIs
- Disadvantages
- The wide variety of DPI types requires thorough patient-training
- DPI performance relies on the strength of inhalation
- Environmental factors have an impact on DPI performance
- Soft mist inhaler (the Respimat)
- CHAPTER 3 CURRENT MARKET SITUATION
- Value and volume of the different inhaler devices
- Sales of pMDIs versus DPIs versus BAIs
- The pressurized metered dose inhalers
- The dry powder inhalers
- The breath-activated metered dose inhalers
- Sales of branded versus generic products
- Sales of CFC-containing versus CFC-free devices
- Value and volume per country
- Pricing of the different inhaler devices
- Pricing of pMDIs versus DPIs versus BAIs
- Pricing of branded versus generic products
- Pricing of CFC-containing versus CFC-free devices
- The availability of devices per molecule
- Inhaled corticosteroids/long-acting beta2-agonist combinations
- Inhaled corticosteroids
- Long-acting beta2-agonists
- Long-acting anticholinergics
- Short-acting beta2-agonists
- CHAPTER 4 THE LINK BETWEEN INHALER DEVICES AND DISEASE CONTROL
- The importance of disease control
- The relation between inhaler devices and disease control
- The relation between inhaler devices and molecules
- Does the ideal inhaler device exist?
- CHAPTER 5 GAINING MARKET SHARE THROUGH INHALER DEVICES
- Spiriva (tiotropium bromide)
- Spiriva differentiated with the help of the Respimat
- The CFC-HFA switch in the US
- HFA as an alternative to CFC
- 3M' s patents will prevent entry of other HFA SABAs
- Impact on individual brands
- Generic ICS/LABA combination products
- CHAPTER 6 PORTABLE INHALER DEVICES IN NON-PULMONARY DISEASES
- Inhaled insulin for the treatment of diabetes
- Where does Exubera' s failure leave the other inhaled insulins in
development?
- Inhaled drugs for the treatment of migraine
- Inhaled apomorphine for the treatment of Parkinson' s disease and
erectile dysfunction
- Inhaled fentanyl for the treatment of breakthrough pain
- Inhaled drugs for the treatment of other non-pulmonary diseases
- CHAPTER 7 THE FUTURE OF PORTABLE INHALER DEVICES
- A differentiating device has biggest impact in medium-mature markets
- The availability of a high number of molecules in the same device may
lead to product uptake
- The role of cost-effectiveness studies will become more important
- The interaction among Big Pharma, generics companies and drug delivery
companies will continue to develop
- The growing importance of generics companies and drug delivery
companies
- BIBLIOGRAPHY
- Papers
- Websites
- Press releases
- Datamonitor reports
- APPENDIX A INDEXED HISTORICAL SALES
- Six major markets
- United States
- France
- Germany
- Italy
- Spain
- United Kingdom
- APPENDIX B INDEXED HISTORICAL VOLUME
- Six major markets
- United States
- France
- Germany
- Italy
- Spain
- United Kingdom
- APPENDIX C PRICING
- Six major markets
- United States
- France
- Germany
- Italy
- Spain
- UK
- APPENDIX D OVERVIEW OF DEVICES AVAILABLE PER MOLECULE AND COUNTRY
- Inhaled corticosteroid/long-acting beta2-agonist combinations
- Inhaled corticosteroids
- Long-acting beta2-agonists
- Long-acting anticholinergics
- Short-acting beta2-agonists
- Short-acting anticholinergics
- Short-acting anticholinergic/beta2-agonist combinations
- APPENDIX E
- Contributing experts
- Report methodology
- About Datamonitor
- About Datamonitor Healthcare
- About the Infectious Disease & Respiratory analysis team
- Disclaimer
- List of Tables
- Table 1: Overview of New Form Codes included in this report
- Table 2: Inhaler assessment grades
- Table 3: Mean scores for pMDI + Volumatic, Turbuhaler and Easi-Breathe
groups for each aspect of technique
- Table 4: Patient inhaler preference
- Table 5: Indexed total value sales by device type, molecule status and
the presence of CFC, in the six major markets, 2003-07
- Table 6: Indexed total volume (standard units) by device type,
molecule status and the presence of CFC, in the six major markets, 2003-07
- Table 7: Indexed total value sales by device type, in the six major
markets, 2003-07
- Table 8: Indexed total value sales of pMDIs by molecule status and the
presence of CFC, in the six major markets, 2003-07
- Table 9: Indexed total value sales of DPIs by molecule status and the
presence of CFC, in the six major markets, 2003-07
- Table 10: Indexed total value sales of BAIs by molecule status and the
presence of CFC, in the six major markets, 2003-07
- Table 11: Indexed total value sales of devices delivering branded
versus generic molecules, across all device types, in the six major
markets, 2003-07
- Table 12: Indexed total value sales of CFC-containing and CFC-free
devices, irrespective of the molecules status, in the six major markets,
2003-07
- Table 13: Pricing of portable inhaler devices per standard unit in the
six major markets, 2003-07
- Table 14: Prices of HFA (levo)salbutamol products in 2007
- Table 15: Inhaled insulin products
- Table 16: Number of asthma patients using single or multiple inhaler
devices and proportion of those patients with inadequate technique, over
two time periods
- Table 17: Indexed total sales by device type, molecule status and the
presence of CFC, in the six major markets, 2003-07
- Table 18: Indexed total sales by device type, molecule status and the
presence of CFC, in the US, 2003-07
- Table 19: Indexed total sales by device type, molecule status and the
presence of CFC, in France, 2003-07
- Table 20: Indexed total sales by device type, molecule status and the
presence of CFC, in Germany, 2003-07
- Table 21: Indexed total sales by device type, molecule status and the
presence of CFC, in Italy, 2003-07
- Table 22: Indexed total sales by device type, molecule status and the
presence of CFC, in Spain, 2003-07
- Table 23: Indexed total sales by device type, molecule status and the
presence of CFC, in the UK, 2003-07
- Table 24: Indexed total volume by device type, molecule status and the
presence of CFC, in the six major markets, 2003-07
- Table 25: Indexed total volume by device type, molecule status and the
presence of CFC, in the US, 2003-07
- Table 26: Indexed total volume by device type, molecule status and the
presence of CFC, in France, 2003-07
- Table 27: Indexed total volume by device type, molecule status and the
presence of CFC, in Germany, 2003-07
- Table 28: Indexed total volume by device type, molecule status and the
presence of CFC, in Italy, 2003-07
- Table 29: Indexed total volume by device type, molecule status and the
presence of CFC, in Spain, 2003-07
- Table 30: Indexed total volume by device type, molecule status and the
presence of CFC, in the UK, 2003-07
- Table 31: Pricing of portable inhaler devices per standard unit in the
six major markets, 2003-07
- Table 32: Pricing of portable inhaler devices per standard unit in the
US, 2003-07
- Table 33: Pricing of portable inhaler devices per standard unit in
France, 2003-07
- Table 34: Pricing of portable inhaler devices per standard unit in
Germany, 2003-07
- Table 35: Pricing of portable inhaler devices per standard unit in
Italy, 2003-07
- Table 36: Pricing of portable inhaler devices per standard unit in
Spain, 2003-07
- Table 37: Pricing of portable inhaler devices per standard unit in the
UK, 2003-07
- Table 38: Overview of devices per country delivering inhaled
corticosteroid/long-acting beta2-agonist combinations, 2007
- Table 39: Overview of devices per country delivering inhaled
corticosteroids, 2007
- Table 40: Overview of devices per country delivering long-acting
beta2-agonists, 2007
- Table 41: Overview of devices per country delivering long-acting
anticholinergics, 2007
- Table 42: Overview of devices per country delivering short-acting
beta2-agonists, 2007
- Table 43: Overview of devices per country delivering short-acting
anticholinergics, 2007
- Table 44: Overview of devices per country delivering short-acting
anticholinergic/beta2-agonist combinations, 2007
- List of Figures
- Figure 1: Timeline of the development of inhaler devices for pulmonary
diseases
- Figure 2: Advantages and disadvantages of the main three types of
portable inhaler devices
- Figure 3: A pressurized metered dose inhaler
- Figure 4: Market share of pMDIs in the total portable inhaler market
in Europe, 2007
- Figure 5: pMDI-dependent errors made by patients when using their
usual inhaler
- Figure 6: A breath-activated metered dose inhaler
- Figure 7: Patients' perception of the ease of use of a pMDI and a BAI
- Figure 8: Distribution of NHS costs for BAI and standard pMDI patients
- Figure 9: Several types of dry powder inhalers
- Figure 10: Instructions for DPI use from patient information leaflets
- Figure 11: The Respimat Soft Mist Inhaler (SMI)
- Figure 12: Sales of inhaled drugs in the six major markets, 2006-16
- Figure 13: The asthma/COPD market by method of drug delivery, 2007
- Figure 14: Indexed total value sales by device type, molecule status
and the presence of CFC, in the six major markets, 2003-07
- Figure 15: Indexed total volume (standard units) by device type,
molecule status and the presence of CFC, in the six major markets, 2003-07
- Figure 16: Indexed total value sales by device type, in the six major
markets, 2003-07
- Figure 17: Indexed total value sales of pMDIs by molecule status and
the presence of CFC, in the six major markets, 2003-07
- Figure 18: Indexed total value sales of DPIs by molecule status and
the presence of CFC, in the six major markets, 2003-07
- Figure 19: Indexed total value sales of BAIs by molecule status and
the presence of CFC, in the six major markets, 2003-07
- Figure 20: Indexed total value sales of devices delivering branded
versus generic molecules, across all device types, in the six major
markets, 2003-07
- Figure 21: Indexed total value sales of CFC-containing and CFC-free
devices, irrespective of the molecules status, in the six major markets,
2003-07
- Figure 22: Value and volume shares of the different types of devices
in the US, 2007
- Figure 23: Value and volume shares of the different types of devices
in France, 2007
- Figure 24: Value and volume shares of the different types of devices
in Germany, 2007
- Figure 25: Value and volume shares of the different types of devices
in Italy, 2007
- Figure 26: Value and volume shares of the different types of devices
in Spain, 2007
- Figure 27: Value and volume shares of the different types of devices
in the UK, 2007
- Figure 28: The average price per SU for the four main device types in
the six major markets, 2003-07
- Figure 29: The average price per SU for branded and generic molecules
across all device types in the six major markets, 2003-07
- Figure 30: The average price per SU for CFC and CFC-free devices
across all types in the six major markets, 2003-07
- Figure 31: Overview of the links between the device and disease control
- Figure 32: Levels of asthma control according to the GINA guidelines
- Figure 33: Characteristics of an ideal inhaler device
- Figure 34: Factors influencing inhaler choice
- Figure 35: Key drivers and resistors for the success of inhaled drug
delivery in non-pulmonary diseases
- Figure 36: Reasons why Exubera (inhaled insulin) failed
- Figure 37: Overview of the characteristics of three types of
asthma/COPD markets per drug class, 2007
- Figure 38: Overview of the inhaled drug delivery sector
|
|
|
|
|
|
View Cart
